JP2023529908A - Ｂｒｍ標的化化合物及び関連する使用方法 - Google Patents

Ｂｒｍ標的化化合物及び関連する使用方法 Download PDF

Info

Publication number
JP2023529908A
JP2023529908A JP2022575824A JP2022575824A JP2023529908A JP 2023529908 A JP2023529908 A JP 2023529908A JP 2022575824 A JP2022575824 A JP 2022575824A JP 2022575824 A JP2022575824 A JP 2022575824A JP 2023529908 A JP2023529908 A JP 2023529908A
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
groups
compound
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022575824A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023529908A5 (enExample
Inventor
ポール コームズ，アンドリュー
リン，ホン
ピティス，フィリップ
ルー，リアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prelude Therapeutics Inc
Original Assignee
Prelude Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prelude Therapeutics Inc filed Critical Prelude Therapeutics Inc
Publication of JP2023529908A publication Critical patent/JP2023529908A/ja
Publication of JP2023529908A5 publication Critical patent/JP2023529908A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022575824A 2020-06-09 2021-06-09 Ｂｒｍ標的化化合物及び関連する使用方法 Pending JP2023529908A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063036811P 2020-06-09 2020-06-09
US63/036,811 2020-06-09
PCT/US2021/036664 WO2021252666A1 (en) 2020-06-09 2021-06-09 Brm targeting compounds and associated methods of use

Publications (2)

Publication Number Publication Date
JP2023529908A true JP2023529908A (ja) 2023-07-12
JP2023529908A5 JP2023529908A5 (enExample) 2024-06-18

Family

ID=76731093

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022575824A Pending JP2023529908A (ja) 2020-06-09 2021-06-09 Ｂｒｍ標的化化合物及び関連する使用方法

Country Status (17)

Country Link
US (2) US11702423B2 (enExample)
EP (2) EP4161935B1 (enExample)
JP (1) JP2023529908A (enExample)
KR (1) KR20230037549A (enExample)
CN (1) CN115867554B (enExample)
AU (1) AU2021289730A1 (enExample)
BR (1) BR112022025061A2 (enExample)
CA (1) CA3185888A1 (enExample)
DK (1) DK4161935T3 (enExample)
ES (1) ES3034380T3 (enExample)
FI (1) FI4161935T3 (enExample)
IL (1) IL298933B2 (enExample)
MX (1) MX2022015732A (enExample)
PL (1) PL4161935T3 (enExample)
PT (1) PT4161935T (enExample)
WO (1) WO2021252666A1 (enExample)
ZA (1) ZA202213711B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
US12454520B2 (en) 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US12624044B2 (en) 2019-06-10 2026-05-12 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
US11679109B2 (en) 2019-12-23 2023-06-20 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
WO2021133917A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
WO2022099117A1 (en) * 2020-11-06 2022-05-12 Prelude Therapeutics Incorporated Brm targeting compounds and associated methods of use
US12606568B2 (en) 2020-12-09 2026-04-21 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
WO2023278402A1 (en) * 2021-06-28 2023-01-05 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
JP2024533990A (ja) * 2021-08-09 2024-09-18 ジェネンテック， インコーポレイテッド Ｂｒｍの調節に使用するためのフェノール誘導体
AU2023270000A1 (en) * 2022-05-10 2024-11-28 Foghorn Therapeutics Inc. Pyrazine derivatives and uses thereof
JP2025521091A (ja) * 2022-05-10 2025-07-08 プレリュード・セラピューティクス・インコーポレイテッド がんの治療のためのｓｍａｒｃａ４タンパク質分解因子としての６，６ａ，７，８，９，１０－ヘキサヒドロ－５ｈ－ピラジノ［１’，２’：４，５］ピラジノ［２，３－ｃ］ピリダジン誘導体
WO2024064316A1 (en) * 2022-09-23 2024-03-28 Regents Of The University Of Michigan Compounds and compositions as smarca2/4 inhibitors and uses thereof
WO2024064328A1 (en) * 2022-09-23 2024-03-28 Regents Of The University Of Michigan Compounds and compositions as smarca2/4 degraders and uses thereof
AU2023356925A1 (en) * 2022-10-03 2025-04-24 Prelude Therapeutics Incorporated Improved treatment of cancers using combinations of SMARCA2 degraders and KRAS targeting therapies
EP4695250A1 (en) 2023-04-12 2026-02-18 Aurigene Oncology Limited Tetracyclic compounds as smarca2 and/or smarca4 degraders
WO2025076351A1 (en) 2023-10-04 2025-04-10 Prelude Therapeutics Incorporated Combination treatment regimens - smarca2 degrader with gemcitabine
US20250114354A1 (en) 2023-10-04 2025-04-10 Prelude Therapeutics Incorporated Combination treatment regimens - smarca2 degrader with pd-1 inhibitors
US20260115189A1 (en) 2023-10-04 2026-04-30 Prelude Therapeutics Incorporated Combination Treatment Regimens - SMARCA2 Degrader With Taxane Anticancer Agent
WO2025106482A1 (en) * 2023-11-13 2025-05-22 Oncopia Therapeutics, Inc. D/B/A Sk Life Science Labs Compounds and compositions as smarca2/4 degraders and uses thereof
WO2025193454A1 (en) 2024-03-01 2025-09-18 Prelude Therapeutics Incorporated Brm and brg1 targeting antibody-drug conjugates and methods of use thereof
WO2026039756A1 (en) * 2024-08-16 2026-02-19 Prelude Therapeutics Incorporated Methods of treating cancer using a smarca2 degrader
WO2026090411A1 (en) * 2024-10-23 2026-04-30 Prelude Therapeutics Incorporated Brm and brg1 targeting compounds and associated methods of use
CN119638700B (zh) * 2024-11-01 2025-11-14 中科中山药物创新研究院 一种nsd2降解剂及其应用
WO2026152359A1 (en) * 2025-01-17 2026-07-23 Prelude Therapeutics Incorporated Polymorphic compounds and uses thereof
WO2026156670A1 (en) 2025-01-24 2026-07-30 Prelude Therapeutics Incorporated Processes for making smarca2 degraders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023509394A (ja) * 2019-12-23 2023-03-08 カイメラ セラピューティクス， インコーポレイテッド Ｓｍａｒｃａ分解剤およびそれらの使用
JP2023549341A (ja) * 2020-11-06 2023-11-24 プレリュード・セラピューティクス・インコーポレイテッド Ｂｒｍ標的化化合物及び関連する使用方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
MA41598A (fr) * 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
GB2554071A (en) 2016-09-14 2018-03-28 Univ Dundee Small molecules
IL325835A (en) 2016-12-23 2026-03-01 Univ Yale Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
IL300417A (en) 2017-01-26 2023-04-01 Arvinas Operations Inc Bifunctional benzothiophene compounds, preparations containing them and their use in therapy
WO2019084026A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HETEROCYCLIC COMPOUNDS AND METHODS OF USE
WO2019084030A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
AU2019249849C1 (en) 2018-04-01 2022-09-29 Arvinas Operations, Inc. BRM targeting compounds and associated methods of use
US12539292B2 (en) 2018-04-01 2026-02-03 Arvinas Operations, Inc. BRM targeting compounds and associated methods of use
US20220324880A1 (en) 2019-06-10 2022-10-13 Kymara Therapeutics, Inc. Smarca inhibitors and uses thereof
US20230087825A1 (en) 2019-06-10 2023-03-23 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
US12624044B2 (en) 2019-06-10 2026-05-12 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
WO2021133917A1 (en) * 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023509394A (ja) * 2019-12-23 2023-03-08 カイメラ セラピューティクス， インコーポレイテッド Ｓｍａｒｃａ分解剤およびそれらの使用
JP2023549341A (ja) * 2020-11-06 2023-11-24 プレリュード・セラピューティクス・インコーポレイテッド Ｂｒｍ標的化化合物及び関連する使用方法

Also Published As

Publication number Publication date
EP4161935A1 (en) 2023-04-12
IL298933B1 (en) 2026-04-01
IL298933B2 (en) 2026-08-01
US20240018158A1 (en) 2024-01-18
BR112022025061A2 (pt) 2023-01-31
EP4570319A2 (en) 2025-06-18
ZA202213711B (en) 2026-04-29
EP4161935B1 (en) 2025-05-21
AU2021289730A1 (en) 2023-01-19
DK4161935T3 (da) 2025-08-18
EP4570319A3 (en) 2025-08-20
MX2022015732A (es) 2023-02-13
CA3185888A1 (en) 2021-12-16
WO2021252666A1 (en) 2021-12-16
US11702423B2 (en) 2023-07-18
AU2021289730A8 (en) 2023-02-02
US20220033409A1 (en) 2022-02-03
KR20230037549A (ko) 2023-03-16
IL298933A (en) 2023-02-01
PL4161935T3 (pl) 2025-09-08
CN115867554B (zh) 2025-09-02
FI4161935T3 (fi) 2025-08-19
ES3034380T3 (en) 2025-08-18
CN115867554A (zh) 2023-03-28
PT4161935T (pt) 2025-08-14

Similar Documents

Publication Publication Date Title
CN115867554B (zh) Brm靶向化合物和相关使用方法
CN114667167B (zh) 用于治疗癌症的杂环化合物
EP4306529B1 (en) Fgfr inhibitors and methods of use thereof
KR20230171979A (ko) Bcl6 단백질 분해의 조절제 및 관련 사용 방법
JP2025521091A (ja) がんの治療のためのｓｍａｒｃａ４タンパク質分解因子としての６，６ａ，７，８，９，１０－ヘキサヒドロ－５ｈ－ピラジノ［１’，２’：４，５］ピラジノ［２，３－ｃ］ピリダジン誘導体
CA2887912A1 (en) Bicyclic heterocycle compounds and their uses in therapy
CN120418251A (zh) Brm靶向化合物和相关使用方法
CN119053600A (zh) 用于治疗癌症的杂环化合物
CN118632841A (zh) 用于治疗癌症的杂环化合物
JP7281834B2 (ja) Ｐｄ－ｌ１拮抗薬化合物
IL319211A (en) Triazine compounds and their uses
KR20230098078A (ko) 신규한 바이사이클릭 헤테로사이클릴 화합물 및 이의 용도
HK40128204A (en) Brm targeting compounds and associated methods of use
EA048707B1 (ru) Brm направленные соединения и связанные способы применения
EA050840B1 (ru) Brm направленные соединения и связанные способы применения
EP4495111A1 (en) Novel compound and use thereof for inhibiting checkpoint kinase 2
WO2025117881A1 (en) Compounds and methods for inhibiting autophagy
JP2026513938A (ja) Ｉｒａｋ４ ｐｒｏｔａｃ
HK40078801B (en) Heterocyclic compounds for use in the treatment of cancer
HK40078801A (en) Heterocyclic compounds for use in the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240607

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240607

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251006

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260512